Skip to main content Accessibility help
×
Hostname: page-component-84b7d79bbc-g5fl4 Total loading time: 0 Render date: 2024-07-29T06:22:56.814Z Has data issue: false hasContentIssue false

13 - Myelodysplastic/myeloproliferative neoplasms

from Section 2 - Neoplastic hematopathology

Published online by Cambridge University Press:  03 May 2011

John Kim Choi
Affiliation:
University of Pennsylvania School of Medicine
Maria A. Proytcheva
Affiliation:
Northwestern University Medical School, Illinois
Get access

Summary

Introduction

Myelodysplastic/myeloproliferative neoplasms are hematopoietic diseases with features of both myelodysplastic syndrome (MDS) and myeloproliferative neoplasm (MPN). In the past, these disorders were grouped as MDS, but they are now grouped as a distinct subentity in the latest classification scheme of hematopoietic neoplasms by the World Health Organization (WHO) [1, 2]. The MDS/MPN category includes chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML), and myelodysplastic/myeloproliferative neoplasm, unclassifiable. This chapter will focus on JMML, which is unique to the pediatric population. CMML in children is considered a secondary or therapy-related MDS [3], and aCML does not occur in the pediatric population [4].

Juvenile myelomonocytic leukemia (JMML)

Synonyms

Juvenile chronic myelomonocytic leukemia, juvenile chronic myeloid leukemia, juvenile granulocytic leukemia, monosomy 7 syndrome, infantile monosomy 7 syndrome.

Epidemiology

JMML is a rare disorder with an incidence of 0.6 per 1 million children, and represents approximately 1.6% of childhood leukemias [5, 6]. The age of presentation ranges from 0 to 11 years, with 40%, 90%, and 98% of the cases presenting at under 1, 4, and 10 years of age, respectively [7, 8]. Boys are affected more frequently, with a male to female ratio of 2 : 1.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Harris, NL, Jaffe, ES, Diebold, J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology. 2000;36(1):69–86.CrossRefGoogle Scholar
Swerdlow, SH, Campo, E, Harris, NL, et al. (eds.). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th edn.). Lyon: IARC Press; 2008, 439.Google Scholar
Hasle, H, Niemeyer, CM, Chessells, JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17(2):277–282.CrossRefGoogle ScholarPubMed
Hernandez, JM, del Canizo, MC, Cuneo, A, et al. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Annals of Oncology. 2000;11(4):441–444.CrossRefGoogle ScholarPubMed
Hasle, H. Myelodysplastic syndromes in childhood – classification, epidemiology, and treatment. Leukemia & Lymphoma. 1994;13(1–2):11–26.CrossRefGoogle Scholar
Luna-Fineman, S, Shannon, KM, Atwater, SK, et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood. 1999;93(2):459–466.Google ScholarPubMed
Arico, M, Biondi, A, Pui, CH. Juvenile myelomonocytic leukemia. Blood. 1997;90(2):479–488.Google ScholarPubMed
Niemeyer, CM, Arico, M, Basso, G, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood. 1997;89(10):3534–3543.Google Scholar
Vail JT Jr., Adler KR, Rothenberg, J. Cutaneous xanthomas associated with chronic myelomonocytic leukemia. Archives of Dermatology. 1985;121(10):1318–1320.CrossRefGoogle ScholarPubMed
Sires, UI, Mallory, SB, Hess, JL, et al. Cutaneous presentation of juvenile chronic myelogenous leukemia: a diagnostic and therapeutic dilemma. Pediatric Dermatology. 1995;12(4):364–368.CrossRefGoogle ScholarPubMed
Matsumoto, K, Miki, J, Matsuzaki, S, Koike, K, Saida, T. Skin infiltration of juvenile myelomonocytic leukemia. The Journal of Dermatology. 2004;31(9):748–751.CrossRefGoogle ScholarPubMed
Tartaglia, M, Niemeyer, CM, Fragale, A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nature Genetics. 2003;34(2):148–150.CrossRefGoogle ScholarPubMed
Jongmans, M, Sistermans, EA, Rikken, A, et al. Genotypic and phenotypic characterization of Noonan syndrome: new data and review of the literature. American Journal of Medical Genetics. Part A. 2005;134(2):165–170.CrossRefGoogle Scholar
Kratz, CP, Niemeyer, CM, Castleberry, RP, et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood. 2005;106(6):2183–2185.CrossRefGoogle ScholarPubMed
Loh, ML, Vattikuti, S, Schubbert, S, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood. 2004;103(6):2325–2331.CrossRefGoogle ScholarPubMed
Friebert, SE, Shepardson, LB, Shurin, SB, Rosenthal, GE, Rosenthal, NS. Pediatric bone marrow cellularity: are we expecting too much?Journal of Pediatric Hematology/Oncology. 1998;20(5):439–443.CrossRefGoogle ScholarPubMed
Hess, JL, Zutter, MM, Castleberry, RP, Emanuel, PD. Juvenile chronic myelogenous leukemia. American Journal of Clinical Pathology. 1996;105(2):238–248.CrossRefGoogle ScholarPubMed
Metelitsa, LS, Weinberg, KI, Emanuel, PD, Seeger, RC. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia. 2003;17(6):1068–1077.CrossRefGoogle ScholarPubMed
Ng, CS, Lam, TK, Chan, JK, et al. Juvenile chronic myeloid leukemia. A malignancy of S-100 protein-positive histiocytes. American Journal of Clinical Pathology. 1988;90(5):575–582.CrossRefGoogle ScholarPubMed
Malcovati, L, Della Porta, MG, Lunghi, M, et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia. 2005;19(5):776–783.CrossRefGoogle ScholarPubMed
Kussick, SJ, Fromm, JR, Rossini, A, et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. American Journal of Clinical Pathology. 2005;124(2):170–181.CrossRefGoogle ScholarPubMed
Pinkel, D. Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood. 1998;89(1):365–367.Google Scholar
Herrod, HG, Dow, LW, Sullivan, JL. Persistent Epstein-Barr virus infection mimicking juvenile chronic myelogenous leukemia: immunologic and hematologic studies. Blood. 1983;61(6):1098–1104.Google ScholarPubMed
Stollmann, B, Fonatsch, C, Havers, W. Persistent Epstein-Barr virus infection associated with monosomy 7 or chromosome 3 abnormality in childhood myeloproliferative disorders. British Journal of Haematology. 1985;60(1):183–196.CrossRefGoogle ScholarPubMed
Kirby, MA, Weitzman, S, Freedman, MH. Juvenile chronic myelogenous leukemia: differentiation from infantile cytomegalovirus infection. The American Journal of Pediatric Hematology/Oncology. 1990;12(3):292–296.CrossRefGoogle ScholarPubMed
Yetgin, S, Cetin, M, Yenicesu, I, Ozaltin, F, Uckan, D. Acute parvovirus B19 infection mimicking juvenile myelomonocytic leukemia. European Journal of Haematology. 2000;65(4):276–278.CrossRefGoogle ScholarPubMed
Lorenzana, A, Lyons, H, Sawaf, H, et al. Human herpesvirus 6 infection mimicking juvenile myelomonocytic leukemia in an infant. Journal of Pediatric Hematology/Oncology. 2002;24(2):136–141.CrossRefGoogle ScholarPubMed
Emanuel, PD, Bates, LJ, Castleberry, RP, Gualtieri, RJ, Zuckerman, KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood. 1991;77(5):925–929.Google ScholarPubMed
Cambier, N, Baruchel, A, Schlageter, MH, et al. Chronic myelomonocytic leukemia: from biology to therapy. Hematology and Cell Therapy. 1997;39(2):41–48.CrossRefGoogle Scholar
Xu, GF, O'Connell, P, Viskochil, D, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell. 1990;62(3):599–608.CrossRefGoogle ScholarPubMed
Ballester, R, Marchuk, D, Boguski, M, et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell. 1990;63(4):851–859.CrossRefGoogle ScholarPubMed
Niihori, T, Aoki, Y, Ohashi, H, et al. Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia. Journal of Human Genetics. 2005;50(4):192–202.CrossRefGoogle ScholarPubMed
Mohi, MG, Williams, IR, Dearolf, CR, et al. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell. 2005;7(2):179–191.CrossRefGoogle ScholarPubMed
Side, , Emanuel, PD, Taylor, B, et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood. 1998;92(1):267–272.Google ScholarPubMed
Miles, DK, Freedman, MH, Stephens, K, et al. Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders. Blood. 1996;88(11):4314–4320.Google ScholarPubMed
Kalra, R, Paderanga, DC, Olson, K, Shannon, KM. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood. 1994;84(10):3435–3439.Google ScholarPubMed
Miyauchi, J, Asada, M, Sasaki, M, et al. Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood. 1994;83(8):2248–2254.Google ScholarPubMed
Jacks, T, Shih, TS, Schmitt, EM, et al. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nature Genetics. 1994;7(3):353–361.CrossRefGoogle ScholarPubMed
Largaespada, DA, Brannan, CI, Jenkins, NA, Copeland, NG. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nature Genetics. 1996;12(2):137–143.CrossRefGoogle ScholarPubMed
Gitler, AD, Kong, Y, Choi, JK, et al. Tie2-Cre-induced inactivation of a conditional mutant Nf1 allele in mouse results in a myeloproliferative disorder that models juvenile myelomonocytic leukemia. Pediatric Research. 2004;55(4):581–584.CrossRefGoogle Scholar
Lauchle, JO, Braun, BS, Loh, ML, Shannon, K. Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatric Blood and Cancer. 2006;46(5):579–585.CrossRefGoogle ScholarPubMed
Amenomori, T, Tomonaga, M, Yoshida, Y, et al. Cytogenetic evidence for partially committed myeloid progenitor cell origin of chronic myelomonocytic leukaemia and juvenile chronic myeloid leukaemia: both granulocyte-macrophage precursors and erythroid precursors carry identical marker chromosome. British Journal of Haematology. 1986;64(3):539–546.CrossRefGoogle ScholarPubMed
Busque, L, Gilliland, DG, Prchal, JT, et al. Clonality in juvenile chronic myelogenous leukemia. Blood. 1995;85(1):21–30.Google ScholarPubMed
Papayannopoulou, T, Nakamoto, B, Anagnou, NP, et al. Expression of embryonic globins by erythroid cells in juvenile chronic myelocytic leukemia. Blood. 1991;77(12):2569–2576.Google ScholarPubMed
Scrideli, CA, Baruffi, MR, Rogatto, SR, et al. B lineage acute lymphoblastic leukemia transformation in a child with juvenile myelomonocytic leukemia, type 1 neurofibromatosis and monosomy of chromosome 7. Possible implications in the leukemogenesis. Leukemia Research. 2003;27(4):371–374.CrossRefGoogle Scholar
Cooper, LJ, Shannon, KM, Loken, MR, et al. Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell. Blood. 2000;96(6):2310–2313.Google ScholarPubMed
Hasle, H, Arico, M, Basso, G, et al. Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. European Working Group on MDS in Childhood (EWOG-MDS). Leukemia. 1999;13(3):376–385.CrossRefGoogle Scholar
Choong, K, Freedman, MH, Chitayat, D, et al. Juvenile myelomonocytic leukemia and Noonan syndrome. Journal of Pediatric Hematology/Oncology. 1999;21(6):523–527.CrossRefGoogle ScholarPubMed
Bader-Meunier, B, Tchernia, G, Mielot, F, et al. Occurrence of myeloproliferative disorder in patients with Noonan syndrome. Journal of Pediatrics. 1997;130(6):885–889.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×